Unveiling the Future of Blockbuster Drugs: What Lies Ahead for Pharmaceutical Powerhouses?

Since the introduction of Tagamet (cimetidine) in 1986, the first-ever blockbuster drug with sales exceeding $1 billion, pharmaceutical companies have been relentlessly pursuing the development of drugs that achieve blockbuster status. These drugs generate substantial revenue and are the epitome of success in the industry. Over the past four decades, blockbuster drugs have consistently emerged each year, contributing to the continuous growth of global sales in the pharmaceutical market.

However, the status of being a blockbuster drug is not guaranteed to last a lifetime. Take, for example, Pfizer's Covid-19 vaccine, Comirnaty, which achieved record-breaking sales of $37.8 billion in 2022. While it is currently among the top 10 best-selling drugs globally, its sales are projected to decline significantly in 2024, possibly falling out of the top 10 entirely. This exemplifies the transient nature of blockbuster drugs, influenced by the evolving demands and dynamics of the healthcare landscape.

On the other hand, some blockbuster drugs have enjoyed remarkable longevity. Humilar, the perennial drug king, has consistently held the second spot in sales. However, the emergence of biosimilars is expected to impact its position in 2023, potentially causing it to drop out of the top 10 in 2024.

Looking ahead to 2024, one drug poised to claim the coveted blockbuster status is Eli Lilly's weight-loss drug, Zepbound (tirzepatide). With its recent approval and market entry, Zepbound has already shown promising prescription numbers, with estimated sales reaching $2.1 billion in 2024. Another potential blockbuster is Sarepta's Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), projected to generate $1.4 billion in sales in 2024. Despite facing challenges during its marketing journey, Elevidys remains a frontrunner in the race for blockbuster status.

Novartis's Pluvicto, a radioactive antitumor drug, is also expected to achieve blockbuster status in 2024. Pluvicto's potential expansion into a larger patient population could significantly boost its profits. Similarly, Madrigal Pharmaceuticals' resmetirom, currently in phase 3 trials, holds promise as a potential blockbuster for the treatment of nonalcoholic steatohepatitis (NASH), a condition with a broad patient base.

UCB's BIMZELX® (Bimekizumab) has already gained FDA approval for the treatment of moderate to severe plaque psoriasis. With an estimated peak global sales of at least €4 billion, BIMZELX is set to make a significant impact in the pharmaceutical market.

Biogen's ZURZUVAE™ (zuranolone) for postpartum depression and VEOZAH (fezolinetant) for vasomotor symptoms caused by menopause are among the other potential blockbuster drugs with substantial projected sales.

As the pharmaceutical landscape evolves, the pursuit of blockbuster drugs remains a driving force for pharmaceutical companies. The success or failure of these drugs heavily relies on factors such as market demand, competition, regulatory approvals, and evolving treatment paradigms. The future of blockbuster drugs will continue to shape the strategies and fortunes of pharmaceutical powerhouses, paving the way for groundbreaking advancements in healthcare.